Antiatherogenic effect of Caps HT2, a herbal Ayurvedic medicine formulation

The antiatherogenic effect of a herbal formulation, Caps HT2, was evaluated as antioxidant, anticoagulant, platelet antiaggregatory, lipoprotein lipase releasing, anti-inflammatory and hypolipidaemic activity in rats. The formulation contained the methanolic extracts of selected parts of plants, Commiphora mukul, Allium sativum, Plumbago indica, Semecarpus anacardium, Hemidesmus indicus, Terminalia arjuna, Tinospora cordifolia, Withania somnifera and Ocimum sanctum. The formulation, Caps HT2 was found to scavenge superoxide and hydroxyl radicals; the IC50 required being 55.0 and 610.0 microg/ml respectively. The lipid peroxidation was found inhibited (50%) by 48.5 microg/ml of Caps HT2. The intravenous administration of the formulation (5 mg/kg) delayed the plasma recalcification time in rabbits and enhanced the release of lipoprotein lipase enzyme significantly (p < 0.001). The formulation also inhibited ADP induced platelet aggregation in vitro, which was comparable to commercial heparin. The anti-inflammatory action of the formulation was significant (p < 0.001) with acute and chronic inflammations induced by carrageenan and formalin respectively in rats. The hypolipidaemic effect of Caps HT2 was significant (p < 0.001) with the administration of the formulation, in diet-induced hyperlipidaemia of rats for a period of 30 days. Oral administration of the formulation, Caps HT2 (100, 200, 300 and 400 mg/kg) significantly raised HDL cholesterol levels. The atherogenic index and the reduction in body weight were significant indicating the effectiveness against hyperlipidaemia and obesity. All these results revealed the therapeutic potential of Caps HT2 against vascular intimal damage and atherogenesis leading to various types of cardiovascular problems.     

Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases

Abstract

The increasing incidence of venous thromboembolism (VTE) in paediatric population has stimulated the development of liquid anticoagulant formulations. Thus our goal is to formulate a liquid formulation of poorly-water soluble anticoagulant, rivaroxaban (RIVA), for paediatric use and to assess the possibility of its intravenous administration in emergencies. Self-nanoemulsifying drug delivery systems (SNEDDSs) were developed and characterized. SNEDDS constituents were estimated from the saturated solubility study followed by plotting the corresponding ternary phase diagrams to determine the best self-emulsified systems. Thermodynamic stability, emulsification, dispersibility, robustness to dilution tests, in vitro dissolution, particle size, and zeta potential were executed to optimize the formulations. The optimized formulation, that composed of Capryol 90:Tween 20:PEG 300 (5:45:50), increased RIVA solubility (285.7-fold than water), it formed nanoemulsion with a particle size of 16.15?nm, PDI of 0.25 and zeta potential of ?21.8. It released 100.83?±?2.78% of RIVA after 5?min. SNEDDS was robust to dilution with oral and parenteral fluids and showed safety to human RBCs. SNEDDS showed enhanced bioavailability after oral and intravenous administration than the oral drug suspension (by 1.25 and 1.26-fold, respectively). Moreover, it exhibited enhanced anticoagulant efficacy in the prevention and treatment of carrageenan-induced thrombosis rat model.     

抗血栓药物的研究进展

血栓栓塞性疾病是引起人类疾病死亡的主要原因之一,随着人们对其发病机制研究与认识的不断深入以及药物设计和筛选技术的日臻成熟,针对各种靶点的新型抗血栓药物不断涌现,如二磷酸腺苷受体阻滞剂、Ⅹ a 因子抑制剂、凝血酶抑制剂等,我国药学研究者也在这些靶向抗血栓药物研究领域取得一定进展。综述我国学者近些年在国内外学术期刊上发表的相关研究论文中所涉及的各类新型抗血小板药物、抗凝血药物和血栓溶解剂的结构、活性和构效关系。     

Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum

Hookworms are hematophagous nematodes capable of growth, development and subsistence in living host systems such as humans and other mammals. Approximately one billion, or one in six, people worldwide are infected by hookworms causing gastrointestinal blood loss and iron deficiency anemia. The hematophagous hookworm Ancylostoma caninum produces a family of small, disulfide-linked protein anticoagulants (75-84 amino acid residues). One of these nematode anticoagulant proteins, NAP5, inhibits the amidolytic activity of factor Xa (fXa) with K(i)=43 pM, and is the most potent natural fXa inhibitor identified thus far. The crystal structure of NAP5 bound at the active site of gamma-carboxyglutamic acid domainless factor Xa (des-fXa) has been determined at 3.1 A resolution, which indicates that Asp189 (fXa, S1 subsite) binds to Arg40 (NAP5, P1 site) in a mode similar to that of the BPTI/trypsin interaction. However, the hydroxyl group of Ser39 of NAP5 additionally forms a hydrogen bond (2.5 A) with His57 NE2 of the catalytic triad, replacing the hydrogen bond of Ser195 OG to the latter in the native structure, resulting in an interaction that has not been observed before. Furthermore, the C-terminal extension of NAP5 surprisingly interacts with the fXa exosite of a symmetry-equivalent molecule forming a short intermolecular beta-strand as observed in the structure of the NAPc2/fXa complex. This indicates that NAP5 can bind to fXa at the active site, or the exosite, and to fX at the exosite. However, unlike NAPc2, NAP5 does not inhibit fVIIa of the fVIIa/TF complex.     

Ultrasound-Assisted Enzyme-Catalyzed Hydrolysis of Collagen to Produce Peptides With Biomedical Potential: Collagenase From Aspergillus terreus UCP1276

Ultrasound has been applied for varied purposes as it provides additional mechanical energy to a system, and is still profitable and straightforward, which are advantages for industrial applications. In this work, ultrasonic treatments were applied to purified collagenase fractions from a fermented extract by Aspergillus terreus UCP 1276 aiming to evaluate the potential effect on collagen hydrolysis. The physical agent was evaluated as an inductor of collagen degradation and consequently as a producer of peptides with anticoagulant activity. The sodium dodecyl sulphate-polyacrylamide gel electrophoresis analyses were also carried out to compare the hydrolysis techniques. The ultrasound (40 kHz, 47.4 W/L) processing was conducted under the same conditions of pH and temperature at different times. The ultrasound-assisted reaction was accelerated in relation to conventional processing. Collagenolytic activity was enhanced and tested in the presence of phenylmethanesulfonyl fluoride inhibitor. Underexposure, the activity was enhanced, reaching more than 72.0% of improvement in relation to the non-exposed enzyme. A period of 30 min of incubation under ultrasound exposure was enough to efficiently produce peptides with biological activity, including anticoagulation and effect on prothrombin time at about 60%. The results indicate that low-frequency ultrasound is an enzymatic inducer with likely commercial applicability accelerating the enzymatic reaction. Bioelectromagnetics. 2020;41:113–120. © 2019 Bioelectromagnetics Society.     

含RGD序列的山蛭素突变体的克隆、表达及性质研究

根据LAP（leech antihemostatic protein）理论,在分析山蛭素和decorsin结构特征的基础上,利用重组PCR方法,删除了山蛭素氨基酸序列的33位至35位,同时分别插入了RGDS和来源于decorsin的一段PRGDADP序列构建成为2种含RGD序列的山蛭素突变体,分别命名为HRGD1和HRGD2.这2种突变体在毕赤酵母菌株GS115中得到成功表达.经过超滤、阳离子交换层析和凝胶过滤层析等纯化步骤之后,得到纯度高于95%的目的蛋白.通过以chromozym TH为底物的凝血酶酰胺水解实验和血小板聚集抑制实验证实了其体外生物学活性,HRGD1和HRGD2抑制凝血酶的动力学常数达到10^-13 mol/L水平,抑制血小板的IC₅₀在10^-6 mol/L水平上.     

A New Class of Pyrethroidal Insecticides; α-Substituted Phenylacetic Acid Esters

A new nucleoside antibiotic, mildiomycin D, was isolated from the culture broth of Streptoverticillium rimofaciens B-98891 as a minor component. The molecular formula of the antibiotic purified by silica gel and ion exchange resin column chromatographies was determined to be C₁₉H₃₀N₈O₈ ? (2H₂O) from its physicochemical data. The ultraviolet and infrared spectra were very similar to those of mildiomycin, a major component. On the basis of ¹H and ¹³C-NMR spectra and acidic hydrolysates of the compound, the chemical structure of the antibiotic was determined as a deoxy compound at the C_8′ position in mildiomycin. Mildiomycin D showed weak activities against Gram-positive and negative bacteria, phytopathogenic fungi and some yeasts, and its activity against Rhodotorula rubura was about 40% that of mildiomycin.     

Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent

1. Download high-res image (226KB)
2. Download full-size image

     

New cross-linked and sulfated derivatives of partially deacetylated hyaluronan: synthesis and preliminary characterization

Partial chemical deacetylation of hyaluronan (HA) has been carried out using known procedures and carefully controlled experimental conditions in order to minimize chain degradation. The sample described herein (deHA) has a degree of deacetylation of about 17%, which corresponds to what required for its further use, but a molecular weight of about 1/25 with respect to the native, starting material. Chemical gels have been prepared with different degrees of cross-linking by means of a Ugi multicomponent condensation reaction involving aqueous deHA, formaldehyde, and cyclohexylisocyanide: the gels are mechanically stable and exhibit good water uptake strongly dependent on the extent of cross-linking, as expected. deHA samples have also been selectively N-sulfated or O-sulfated: the former exhibit anticoagulant properties well exceeding those of the latter and not too inferior to heparin.     

Purification and Amino Acid Sequence of MP-III 4R D49 Phospholipase A2 from Bothrops pirajai Snake Venom, a Toxin with Moderate PLA2 and Anticoagulant Activities and High Myotoxic Activity

MP-III 4R PLA₂ was purified from the venom of Bothrops pirajai venom (Bahia's jararacussu) after three chromatographic steps which started with RP-HPLC. The complete amino acid sequence of MP-III 4R PLA₂ from Bothrops pirajai was determined by amino acid sequencing of reduced and carboxymethylated MP-III 4R and the isolated peptides from clostripain and protease V8 digestion. MP-III 4R is a D49 PLA₂ with 121 amino acid residues and has a molecular weight estimated at 13,800 Da, with 14 half-cysteines. This protein showed moderate PLA₂ and anticoagulant activity. This PLA₂ does not have a high degree of homology with other bothropic PLA₂-like myotoxins (~75%) and nonbothropic myotoxins (~60%). MP-III 4R is a new PLA₂, which was isolated using exclusively analytical and preparative HPLC methods. Based on the N-terminal sequence and biological activities, MP-III 4R was identified as similar to piratoxin-III (PrTX-III), which was isolated by conventional chromatography based on molecular exclusion ion exchange chromatography. Clinical manifestations indicate that at the site of toxin injection, there may be pain of variable intensity, because animals continue to lick the limb. No clinical sign indicating general toxicity was noticed. Myotoxicity was observed in gastrocnemius muscle cells after exposure to MP-III 4R, with a high frequency (70%) of affected muscle fibers.